Navigation Links
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
Date:4/9/2008

- Strong U.S. sales growth to $83.5 million, up 13 percent over

fourth-quarter 2007 and 42 percent over first-quarter 2007 -

CAMBRIDGE, Mass., April 10 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced first-quarter 2008 U.S. net sales of $83.5 million for its flagship product VELCADE, the global market leader for the treatment of patients with relapsed multiple myeloma. These results represent a 13 percent increase over fourth-quarter 2007 and a 42 percent increase over the first-quarter 2007, significantly exceeding the U.S. Wall Street analyst consensus estimate.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"VELCADE sales continue to strengthen, driven primarily by greater use in patients with relapsed multiple myeloma," said Deborah Dunsire, M.D., President and Chief Executive Officer, Millennium. "We expect to see further sales acceleration should the FDA approve VELCADE for, and after we begin to promote for use in patients with, newly diagnosed multiple myeloma. The FDA decision date is June 20, 2008. We believe an approval could potentially double the number of patients with multiple myeloma eligible to benefit from VELCADE."

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD). Millennium is responsible for commercialization of VELCADE in the U.S. and Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Mil
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Millennium Announces $200,000 Purchase Order From Greek Distributor
2. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
3. Millennium Over-Delivers on 2007 Goals and Financial Guidance
4. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
5. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
6. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
7. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
8. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
9. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
10. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
11. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up ... many of them wrote: "Take better care of my furry companion." ... designer clothes and top-brand carrying cases to take the little canine ... might also feel compelled to buy some pricey toys at the ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management ... Product Strategy. In this role, Michelle will work with current ... in the development of iLab products. Her main goal will ... to the scientific community by offering the most advanced, user-friendly, ...
(Date:1/14/2014)... Kinaxis ®, provider of RapidResponse ®, a cloud-based supply ... ( S&OP ) service, is proud to be a gold ... held at the Hilton San Diego Bayfront, January 30 – ... Kaszas , Director of Supply Chain at Amgen, as she ...
(Date:1/14/2014)... 14, 2014 Independent publisher Bitingduck Press, ... Montreal, Canada, has big ideas for 2014 in production ... goals are to produce high-quality, low-cost, DRM-free ebooks and ... businesses. , The first major development will be ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... June 8 CSL Limited (ASX: CSL) and Talecris Biotherapeutics, ... their merger agreement, announced on August 12, 2008, under which ... , , Dr. Brian McNamee, CEO and Managing Director ... Federal Trade Commission (FTC) resolved to block the transaction. ...
... Calif., June 8 Proteolix, Inc. today announced data from ... for the treatment of multiple myeloma at the 14th Congress ... Carfilzomib is the first in a new class of selective, ... of hematologic malignancies and solid tumors. , ...
... 8 /PRNewswire/ -- Pasteuria Bioscience announced that ... Agency (EPA) for Pasteuria usgae . This is ... spp., a natural bacteria prevalent in soil that have ... nematodes. , , "We,re very pleased to ...
Cached Biology Technology:CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement 2CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement 3Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association 2Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association 3Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association 4Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association 5Pasteuria Bioscience Receives EPA Registration for Nematode Control 2
(Date:4/23/2014)... Like a hungry diner ripping open a dinner roll, ... must tear open a hydrogen molecule. Now researchers have ... the two halves of its hydrogen feast. The view ... make the catalyst work better for alternative energy uses. ... shown precisely where the hydrogen halves end up in ...
(Date:4/23/2014)... 23 2014) A team of researchers ... (hNSCs) into the brains of nonhuman primates and ... 24 months found that the hNSCs had differentiated ... cause tumors. , The study will be published ... but is currently freely available on-line as ...
(Date:4/23/2014)... have found evidence of an interaction between prenatal ... behavior in children, especially in girls. , "The ... to prenatal smoking will have behavioral problems. ... Boutwell, Assistant Professor at Sam Houston State University, ... the study. "One possible explanation for this ...
Breaking Biology News(10 mins):Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Study finds long-term survival of human neural stem cells transplanted into primate brain 2Genetics risk, prenatal smoking may predict behavioral problems 2
... head. What do you do? You probably first move out of ... object is. Your brain is able to quickly switch from detecting ... is through a phenomenon called adaptation. A new study in ... Neuroscience details the biological basis of this ability for rapid ...
... , WASHINGTON, D.C., November 21, 2010 -- Jump ropes are ... But what about the underlying physics? How do jump ropes ... Aristoff and Howard Stone of Princeton University have built themselves ... parameters -- rope rotation rate, rope density, diameter, length, and ...
... The Innovative Vector Control Consortium (IVCC) has received $50 ... continue its work to develop new insecticides for the ... malaria, dengue and other neglected tropical diseases. ... grant of $50.7 million over five years from the ...
Cached Biology News:Study reveals neural basis of rapid brain adaptation 2Study reveals neural basis of rapid brain adaptation 3
MOUSE ANTI GUINEA PIG T-CELLS (PAN):FITC Immunogen: Guinea pig peritoneal T-cells...
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
Anti-Goat HRP-AEC Cell & Tissue Staining Kit...
Biology Products: